Internal Medicine
RSSArticles
-
24-Hour Activity Rhythms and Amyloid-β Deposition in the Brain
This study of dementia-free adults found that greater variability of the 24-hour activity rhythm (greater during the daytime as well as during sleep time) with fragmentation of sleep predicted increased deposition of amyloid-β (Aβ), especially in apolipoprotein E 4 (APOE4) carriers.
-
New Injectable Cholesterol-Lowering Drug Trial
A comparison of inclisiran therapy to placebo and ezetimibe therapy over six months in primary prevention patients at low risk of atherosclerotic cardiovascular disease and not taking lipid-lowering therapy has shown that inclisiran subcutaneously every six months reduces low-density lipoprotein cholesterol more than ezetimibe and is comparable to the reported results of high-dose statins taken daily.
-
CT Coronary Artery Calcium Progression After an Initial Score of Zero
A large Korean study of asymptomatic subjects undergoing more than one computed tomography (CT) coronary calcium scoring scan as part of an employment-based health screening has shown that most had scores of 0, and that during a maximum follow-up of 12 years, the majority stayed at 0 on a repeat scan. Also, in those with a coronary artery calcium score of 0 initially, clinically significant scores (> 100) were only found in 4% of scans at 10-year follow-up.
-
Are Weight Gain and Mental Health Bidirectionally Connected?
In an adult population-based cohort study over four years, researchers found that both emotional eating and body dissatisfaction independently mediate the relationships between mental health factors and body mass index trajectories.
-
What Kind of Block?
The electrocardiogram in the figure was obtained from an older adult who presented for evaluation of syncope. What kind of atrioventricular (AV) block is present? Or is the rhythm something other than an AV block?
-
Nipocalimab-aahu Injection (Imaavy)
The U.S. Food and Drug Administration has approved a neonatal Fc-receptor (FcRn) blocker for the treatment of generalized myasthenia gravis. Nipocalimab-aahu is a recombinant human immunoglobulin G1 lambda monoclonal antibody directed at FcRn with high affinity and selectivity.
-
TIA Is Associated with Accelerated Cognitive Decline
The study investigators looked at data from a prospective study of 30,239 Black and white community-dwelling persons aged 45 years or older with cognitive evaluations over the phone every other year until 2022. The researchers documented patients who had transient ischemic attack (TIA) or stroke, and demonstrated that persons who had TIA had a cognitive decline trajectory similar to those patients who had a definite diagnosis of stroke.
-
Looking Beyond LDL in Cardiovascular Risk Screening for Women
In a 30-year prospective study of nearly 28,000 initially healthy U.S. women, baseline levels of high-sensitivity C-reactive protein, low-density lipoprotein cholesterol or lipoprotein(a) independently and additively predicted major cardiovascular events.
-
Measles Outbreaks in the United States
Several measles outbreaks have been active in the United States, with more than 1,000 cases reported already in 2025. Most outbreaks begin as unvaccinated individuals in the United States come into contact with an infected individual who has recently arrived after international travel. Vaccination is effective, but current U.S. vaccine coverage rates are below the 95% rate considered necessary to provide herd immunity.
-
Atrasentan Tablets (Vanrafia)
The U.S. Food and Drug Administration has approved atrasentan, the first selective endothelin A receptor (ETAR) antagonist to reduce proteinuria in adults with immunoglobulin A nephropathy. It was approved under accelerated approval based on surrogate outcome. Continued approval may be contingent on verification of clinical benefit in a confirmatory clinical trial. Atrasentan is distributed by Novartis Pharmaceuticals Corporation as Vanrafia.